Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial

Collapse authors list.
Pettitt, Andrew R ORCID: 0000-0002-0907-8950, Jackson, Richard ORCID: 0000-0002-7814-5088, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Polydoros, Fotis, Yap, Christina, Dodd, James, Bickerstaff, Matthew, Stackpoole, Michael, Khan, Umair T ORCID: 0000-0002-9470-3481, Carruthers, Stacey et al (show 16 more authors) , Oates, Melanie, Lin, Ke, Coupland, Sarah E ORCID: 0000-0002-1464-2069, Menon, Geetha, Kalakonda, Nagesh ORCID: 0000-0002-5300-1360, McCarthy, Helen, Bloor, Adrian, Schuh, Anna, Duncombe, Andrew, Dearden, Claire, Fegan, Christopher, Kennedy, Ben, Walewska, Renata, Marshall, Scott, Fox, Christopher P and Hillmen, Peter (2020) Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105 (12). pp. 2868-2871. ISSN 0390-6078, 1592-8721

Text CLL210 manuscript letter to editor.docx - Author Accepted Manuscript Download (628kB)

Item Type:	Article
Uncontrolled Keywords:	Chronic Lymphocytic Leukemia, alemtuzumab, clinical trial, lenalidomide, ofatumumab
Depositing User:	Symplectic Admin
Date Deposited:	07 May 2020 09:43
Last Modified:	07 Dec 2024 00:54
DOI:	10.3324/haematol.2019.230805
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3086357